Skip to main content
Top
Published in: Arthritis Research & Therapy 2/2014

Open Access 01-04-2014 | Research article

Roles of mast cells in the pathogenesis of inflammatory myopathy

Authors: Masaya Yokota, Kotaro Suzuki, Koji Tokoyoda, Kazuyuki Meguro, Junichi Hosokawa, Shigeru Tanaka, Kei Ikeda, Takashi Mikata, Toshinori Nakayama, Hitoshi Kohsaka, Hiroshi Nakajima

Published in: Arthritis Research & Therapy | Issue 2/2014

Login to get access

Abstract

Introduction

In addition to the pivotal roles of mast cells in allergic diseases, recent data suggest that mast cells play crucial roles in a variety of autoimmune responses. However, their roles in the pathogenesis of autoimmune skeletal muscle diseases have not been clarified despite their distribution in skeletal muscle. Therefore, the objective of this study is to determine the roles of mast cells in the development of autoimmune skeletal muscle diseases.

Methods

The number of mast cells in the affected muscle was examined in patients with dermatomyositis (DM) or polymyositis (PM). The susceptibility of mast cell-deficient WBB6F1-KitW/KitWv mice (W/Wv mice) to a murine model of polymyositis, C protein-induced myositis (CIM), was compared with that of wild-type (WT) mice. The effect of mast cell reconstitution with bone marrow-derived mast cells (BMMCs) on the susceptibility of W/Wv mice to CIM was also evaluated.

Results

The number of mast cells in the affected muscle increased in patients with PM as compared with patients with DM. W/Wv mice exhibited significantly reduced disease incidence and histological scores of CIM as compared with WT mice. The number of CD8+ T cells and macrophages in the skeletal muscles of CIM decreased in W/Wv mice compared with WT mice. Engraftment of BMMCs restored the incidence and histological scores of CIM in W/Wv mice. Vascular permeability in the skeletal muscle was elevated in WT mice but not in W/Wv mice upon CIM induction.

Conclusion

Mast cells are involved in the pathogenesis of inflammatory myopathy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Galli SJ, Nakase S, Tsai M: Mast cells in the development of adaptive immune responses. Nat Immunol. 2005, 6: 135-142. 10.1038/ni1158.CrossRefPubMed Galli SJ, Nakase S, Tsai M: Mast cells in the development of adaptive immune responses. Nat Immunol. 2005, 6: 135-142. 10.1038/ni1158.CrossRefPubMed
2.
go back to reference Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M: Mast cells as “tunable” effector and immunoregulatory cells: recent advances. Annu Rev Immunol. 2005, 23: 749-786. 10.1146/annurev.immunol.21.120601.141025.CrossRefPubMed Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M: Mast cells as “tunable” effector and immunoregulatory cells: recent advances. Annu Rev Immunol. 2005, 23: 749-786. 10.1146/annurev.immunol.21.120601.141025.CrossRefPubMed
3.
go back to reference Sayed BA, Christy A, Quirion MR, Brown MA: The master switch: the role of mast cells in autoimmunity and tolerance. Annu Rev Immunol. 2008, 26: 705-739. 10.1146/annurev.immunol.26.021607.090320.CrossRefPubMed Sayed BA, Christy A, Quirion MR, Brown MA: The master switch: the role of mast cells in autoimmunity and tolerance. Annu Rev Immunol. 2008, 26: 705-739. 10.1146/annurev.immunol.26.021607.090320.CrossRefPubMed
4.
go back to reference Lee DM, Friend DS, Gurish MF, Benoit C, Mathis D, Brenner MB: Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science. 2002, 297: 1689-1692. 10.1126/science.1073176.CrossRefPubMed Lee DM, Friend DS, Gurish MF, Benoit C, Mathis D, Brenner MB: Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science. 2002, 297: 1689-1692. 10.1126/science.1073176.CrossRefPubMed
5.
go back to reference Secor VH, Secor WE, Gutekunst CA, Brown MA: Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J Exp Med. 2006, 191: 813-821.CrossRef Secor VH, Secor WE, Gutekunst CA, Brown MA: Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J Exp Med. 2006, 191: 813-821.CrossRef
6.
go back to reference Geoffrey R, Jia S, Kwitek AE, Woodiff J, Ghosh S, Lernmark A, Wang X, Hessner MJ: Evidence of a functional role for mast cells in the development of type 1 diabetes mellitus in the biobreeding rat. J Immunol. 2006, 177: 7275-7286.CrossRefPubMed Geoffrey R, Jia S, Kwitek AE, Woodiff J, Ghosh S, Lernmark A, Wang X, Hessner MJ: Evidence of a functional role for mast cells in the development of type 1 diabetes mellitus in the biobreeding rat. J Immunol. 2006, 177: 7275-7286.CrossRefPubMed
7.
go back to reference Humphries DE, Wong GW, Friend DS, Gurish MF, Qiu WT, Huang C, Sharpe AH, Stevens RL: Heparin is essential for the storage of specific granule proteases in mast cells. Nature. 1999, 400: 769-772. 10.1038/23481.CrossRefPubMed Humphries DE, Wong GW, Friend DS, Gurish MF, Qiu WT, Huang C, Sharpe AH, Stevens RL: Heparin is essential for the storage of specific granule proteases in mast cells. Nature. 1999, 400: 769-772. 10.1038/23481.CrossRefPubMed
8.
go back to reference Dalakas MC: Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies. Nat Clin Pract Rheumatol. 2006, 2: 219-227. 10.1038/ncprheum0140.CrossRefPubMed Dalakas MC: Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies. Nat Clin Pract Rheumatol. 2006, 2: 219-227. 10.1038/ncprheum0140.CrossRefPubMed
9.
go back to reference Mammen AL: Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol. 2011, 7: 343-354. 10.1038/nrneurol.2011.63.CrossRefPubMed Mammen AL: Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol. 2011, 7: 343-354. 10.1038/nrneurol.2011.63.CrossRefPubMed
10.
go back to reference Sugihara T, Sekine C, Nakae T, Kohyama K, Harigai M, Iwakura Y, Matsumoto Y, Miyasaka N, Kohsaka H: A new murine model to define the critical pathologic and therapeutic mediators of polymyositis. Arthritis Rheum. 2007, 56: 1304-1314. 10.1002/art.22521.CrossRefPubMed Sugihara T, Sekine C, Nakae T, Kohyama K, Harigai M, Iwakura Y, Matsumoto Y, Miyasaka N, Kohsaka H: A new murine model to define the critical pathologic and therapeutic mediators of polymyositis. Arthritis Rheum. 2007, 56: 1304-1314. 10.1002/art.22521.CrossRefPubMed
11.
go back to reference Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). New Engl J Med. 1975, 292: 344-347. 10.1056/NEJM197502132920706.CrossRefPubMed Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). New Engl J Med. 1975, 292: 344-347. 10.1056/NEJM197502132920706.CrossRefPubMed
12.
go back to reference Bohan A, Peter JB: Polymyositis and dermatomyositis (second of two parts). New Engl J Med. 1975, 292: 403-407. 10.1056/NEJM197502202920807.CrossRefPubMed Bohan A, Peter JB: Polymyositis and dermatomyositis (second of two parts). New Engl J Med. 1975, 292: 403-407. 10.1056/NEJM197502202920807.CrossRefPubMed
13.
go back to reference Studynkova JT, Charvat F, Jarosova K, Vencovsky J: The role of MRI in the assessment of polymyositis and dermatomyositis. Rheumatology. 2007, 46: 1174-1179. 10.1093/rheumatology/kem088.CrossRef Studynkova JT, Charvat F, Jarosova K, Vencovsky J: The role of MRI in the assessment of polymyositis and dermatomyositis. Rheumatology. 2007, 46: 1174-1179. 10.1093/rheumatology/kem088.CrossRef
14.
go back to reference Okabe M, Ikawa M, Kominami K, Nakanishi T, Nishimune Y: ‘Green mice’ as a source of ubiquitous green cells. FEBS Lett. 1997, 407: 313-319. 10.1016/S0014-5793(97)00313-X.CrossRefPubMed Okabe M, Ikawa M, Kominami K, Nakanishi T, Nishimune Y: ‘Green mice’ as a source of ubiquitous green cells. FEBS Lett. 1997, 407: 313-319. 10.1016/S0014-5793(97)00313-X.CrossRefPubMed
15.
go back to reference Okiyama N, Sugihara T, Iwakura Y, Yokozeki H, Miyasaka Y, Kohsaka H: Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum. 2009, 60: 2505-2512. 10.1002/art.24689.CrossRefPubMed Okiyama N, Sugihara T, Iwakura Y, Yokozeki H, Miyasaka Y, Kohsaka H: Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum. 2009, 60: 2505-2512. 10.1002/art.24689.CrossRefPubMed
16.
go back to reference Sugihara T, Okiyama N, Suzuki M, Kohyama K, Matsumoto Y, Miyasaka N, Kohsaka H: Definitive engagement of cytotoxic CD8 T cells in C protein-induced myositis, a murine model of polymyositis. Arthritis Rheum. 2010, 62: 3088-3092. 10.1002/art.27625.CrossRefPubMed Sugihara T, Okiyama N, Suzuki M, Kohyama K, Matsumoto Y, Miyasaka N, Kohsaka H: Definitive engagement of cytotoxic CD8 T cells in C protein-induced myositis, a murine model of polymyositis. Arthritis Rheum. 2010, 62: 3088-3092. 10.1002/art.27625.CrossRefPubMed
17.
go back to reference Suzuki K, Verma IM: Phosphorylation of SNAP-23 by IκB Kinase 2 regulates mast cell degranulation. Cell. 2008, 134: 485-495. 10.1016/j.cell.2008.05.050.PubMedCentralCrossRefPubMed Suzuki K, Verma IM: Phosphorylation of SNAP-23 by IκB Kinase 2 regulates mast cell degranulation. Cell. 2008, 134: 485-495. 10.1016/j.cell.2008.05.050.PubMedCentralCrossRefPubMed
18.
go back to reference Nicaise C, Mitrecic D, Demetter P, De Decker R, Authelet M, Boom A, Pochet R: Impaired blood-brain and blood-spinal cord barriers in mutant SOD1-linked ALS rat. Brain Res. 2009, 1301: 152-162.CrossRefPubMed Nicaise C, Mitrecic D, Demetter P, De Decker R, Authelet M, Boom A, Pochet R: Impaired blood-brain and blood-spinal cord barriers in mutant SOD1-linked ALS rat. Brain Res. 2009, 1301: 152-162.CrossRefPubMed
19.
go back to reference Abraham WM: Tryptase: potential role in airway inflammation and remodeling. Am J Physiol Lung Cell Mol Physiol. 2002, 282: L193-L196.CrossRefPubMed Abraham WM: Tryptase: potential role in airway inflammation and remodeling. Am J Physiol Lung Cell Mol Physiol. 2002, 282: L193-L196.CrossRefPubMed
20.
go back to reference Shrestha S, Wershil B, Sarwark JF, Niewold TB, Philipp T, Pachman LM: Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. Arthritis Rheum. 2010, 62: 2813-2822. 10.1002/art.27529.PubMedCentralCrossRefPubMed Shrestha S, Wershil B, Sarwark JF, Niewold TB, Philipp T, Pachman LM: Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. Arthritis Rheum. 2010, 62: 2813-2822. 10.1002/art.27529.PubMedCentralCrossRefPubMed
21.
go back to reference Binstadt BA, Patel PR, Alencar H, Nigrovic PA, Lee DM, Mahmood U, Weissleder R, Mathis D, Benoit C: Particularities of the vasculature can promote the organ specificity of autoimmune attack. Nat Immunol. 2006, 7: 284-292. 10.1038/ni1306.CrossRefPubMed Binstadt BA, Patel PR, Alencar H, Nigrovic PA, Lee DM, Mahmood U, Weissleder R, Mathis D, Benoit C: Particularities of the vasculature can promote the organ specificity of autoimmune attack. Nat Immunol. 2006, 7: 284-292. 10.1038/ni1306.CrossRefPubMed
22.
go back to reference Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, Barohn RJ, Saperstein DS, Briemberg HR, Ericsson M, Park P, Amato AA: Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005, 57: 664-678. 10.1002/ana.20464.CrossRefPubMed Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, Barohn RJ, Saperstein DS, Briemberg HR, Ericsson M, Park P, Amato AA: Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005, 57: 664-678. 10.1002/ana.20464.CrossRefPubMed
24.
go back to reference Metz M, Grimbaldeston MA, Nakae S, Piliponsky AM, Tsai M, Galli SJ: Mast cells in the promotion and limitation of chronic inflammation. Immunol Rev. 2007, 217: 304-328. 10.1111/j.1600-065X.2007.00520.x.CrossRefPubMed Metz M, Grimbaldeston MA, Nakae S, Piliponsky AM, Tsai M, Galli SJ: Mast cells in the promotion and limitation of chronic inflammation. Immunol Rev. 2007, 217: 304-328. 10.1111/j.1600-065X.2007.00520.x.CrossRefPubMed
25.
go back to reference Galli SJ, Grimbaldeston M, Tsai M: Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol. 2008, 8: 478-486. 10.1038/nri2327.PubMedCentralCrossRefPubMed Galli SJ, Grimbaldeston M, Tsai M: Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol. 2008, 8: 478-486. 10.1038/nri2327.PubMedCentralCrossRefPubMed
26.
go back to reference Reber LL, Marichal T, Galli SJ: New models for analyzing mast cell functions in vivo. Trends in Immunol. 2012, 33: 613-625. 10.1016/j.it.2012.09.008.CrossRef Reber LL, Marichal T, Galli SJ: New models for analyzing mast cell functions in vivo. Trends in Immunol. 2012, 33: 613-625. 10.1016/j.it.2012.09.008.CrossRef
27.
go back to reference Kohsaka H: Current insights in polymyositis and dermatomyositis. Clin Exp Neuroimmunol. 2010, 1: 22-32. 10.1111/j.1759-1961.2009.00002.x.CrossRef Kohsaka H: Current insights in polymyositis and dermatomyositis. Clin Exp Neuroimmunol. 2010, 1: 22-32. 10.1111/j.1759-1961.2009.00002.x.CrossRef
28.
go back to reference Gordon JR: Monocyte chemoattractant peptide-1 expression during cutaneous allergic reactions in mice is mast cell dependent and largely mediates the monocyte recruitment response. J Allergy Clin Immunol. 2000, 106: 110-116. 10.1067/mai.2000.107036.CrossRefPubMed Gordon JR: Monocyte chemoattractant peptide-1 expression during cutaneous allergic reactions in mice is mast cell dependent and largely mediates the monocyte recruitment response. J Allergy Clin Immunol. 2000, 106: 110-116. 10.1067/mai.2000.107036.CrossRefPubMed
Metadata
Title
Roles of mast cells in the pathogenesis of inflammatory myopathy
Authors
Masaya Yokota
Kotaro Suzuki
Koji Tokoyoda
Kazuyuki Meguro
Junichi Hosokawa
Shigeru Tanaka
Kei Ikeda
Takashi Mikata
Toshinori Nakayama
Hitoshi Kohsaka
Hiroshi Nakajima
Publication date
01-04-2014
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 2/2014
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar4512

Other articles of this Issue 2/2014

Arthritis Research & Therapy 2/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.